RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
2019-01-01 Gamucci, T; Pizzuti, L; Natoli, C; Mentuccia, L; Sperduti, I; Barba, M; Sergi, D; Iezzi, L; Maugeri-Sacca, M; Vaccaro, A; Magnolfi, E; Gelibter, A; Barchiesi, G; Magri, V; D'Onofrio, L; Cassano, A; Rossi, E; Botticelli, A; Moscetti, L; Omarini, C; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Mazzotta, M; Bria, E; Foglietta, J; Samaritani, R; Garufi, C; Mariani, L; Barni, S; Mirabelli, R; Sarmiento, R; Graziano, V; Santini, D; Marchetti, P; Tonini, G; Di Lauro, L; Sanguineti, G; Paoletti, G; Tomao, S; De Maria, R; Veltri, E; Paris, I; Giotta, F; Latorre, A; Giordano, A; Ciliberto, G; Vici, P
A Multimeric Synthetic Combinatorial peptide library. A Multimeric Synthetic Combinatorial peptide library
1994-01-01 Wallace, A.; Altamura, S.; Toniatti, C.; Vitelli, A.; Bianchi, E.; Delmastro, P.; Ciliberto, G; A., Pessi
A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice
2016-01-01 Tagliamonte, M; Petrizzo, A; Napolitano, M; Luciano, A; Rea, D; Barbieri, A; Arra, C; Maiolino, P; Tornesello, M; Ciliberto, G; Buonaguro, Fm; Buonaguro, L
A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines
2009-01-01 Peruzzi, D; Dharmapuri, S; Cirillo, A; Bruni, Be; Nicosia, A; Cortese, R; Colloca, S; Ciliberto, G; LA MONICA, N; Aurisicchio, L
A novel method for site-directed mutagenesis: its application to an eukaryotic tRNAPro gene promoter
1982-01-01 Traboni, C.; Ciliberto, G; Cortese, R.
A novel minigene scaffold for therapeutic cancer vaccines
2014-01-01 Aurisicchio, L; Fridman, A; Bagchi, A; Scarselli, E; LA MONICA, N; Ciliberto, G
A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses
2009-01-01 Conforti, A; Peruzzi, D; Gianneti, P; Biondo, A; Ciliberto, G; LA MONICA, N; Aurisicchio, L
A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent
2004-01-01 Savino, R; Ciliberto, G.
A PARADIGM SHIFT FOR ERYTHROPOIETIN: NO LONGER A SPECIALIZED GROWTH FACTOR, BUT RATHER THAN AN ALL-PURPOSE TISSUE-PROTECTIVE AGENT
2004-01-01 Savino, R; Ciliberto, G
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
2022-01-01 Donzelli, Sara; Cioce, Mario; Sacconi, Andrea; Zanconato, Francesca; Daralioti, Theodora; Goeman, Frauke; Orlandi, Giulia; Di Martino, Simona; Fazio, Vito Michele; Alessandrini, Gabriele; Telera, Stefano; Carosi, Mariantonia; Ciliberto, Gennaro; Botti, Claudio; Strano, Sabrina; Piccolo, Stefano; Blandino, Giovanni
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study | 1-gen-2019 | Gamucci, T; Pizzuti, L; Natoli, C; Mentuccia, L; Sperduti, I; Barba, M; Sergi, D; Iezzi, L; Maugeri-Sacca, M; Vaccaro, A; Magnolfi, E; Gelibter, A; Barchiesi, G; Magri, V; D'Onofrio, L; Cassano, A; Rossi, E; Botticelli, A; Moscetti, L; Omarini, C; Fabbri, Ma; Scinto, Af; Corsi, D; Carbognin, L; Mazzotta, M; Bria, E; Foglietta, J; Samaritani, R; Garufi, C; Mariani, L; Barni, S; Mirabelli, R; Sarmiento, R; Graziano, V; Santini, D; Marchetti, P; Tonini, G; Di Lauro, L; Sanguineti, G; Paoletti, G; Tomao, S; De Maria, R; Veltri, E; Paris, I; Giotta, F; Latorre, A; Giordano, A; Ciliberto, G; Vici, P | |
A Multimeric Synthetic Combinatorial peptide library. A Multimeric Synthetic Combinatorial peptide library | 1-gen-1994 | Wallace, A.; Altamura, S.; Toniatti, C.; Vitelli, A.; Bianchi, E.; Delmastro, P.; Ciliberto, G; A., Pessi | |
A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice | 1-gen-2016 | Tagliamonte, M; Petrizzo, A; Napolitano, M; Luciano, A; Rea, D; Barbieri, A; Arra, C; Maiolino, P; Tornesello, M; Ciliberto, G; Buonaguro, Fm; Buonaguro, L | |
A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines | 1-gen-2009 | Peruzzi, D; Dharmapuri, S; Cirillo, A; Bruni, Be; Nicosia, A; Cortese, R; Colloca, S; Ciliberto, G; LA MONICA, N; Aurisicchio, L | |
A novel method for site-directed mutagenesis: its application to an eukaryotic tRNAPro gene promoter | 1-gen-1982 | Traboni, C.; Ciliberto, G; Cortese, R. | |
A novel minigene scaffold for therapeutic cancer vaccines | 1-gen-2014 | Aurisicchio, L; Fridman, A; Bagchi, A; Scarselli, E; LA MONICA, N; Ciliberto, G | |
A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses | 1-gen-2009 | Conforti, A; Peruzzi, D; Gianneti, P; Biondo, A; Ciliberto, G; LA MONICA, N; Aurisicchio, L | |
A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent | 1-gen-2004 | Savino, R; Ciliberto, G. | |
A PARADIGM SHIFT FOR ERYTHROPOIETIN: NO LONGER A SPECIALIZED GROWTH FACTOR, BUT RATHER THAN AN ALL-PURPOSE TISSUE-PROTECTIVE AGENT | 1-gen-2004 | Savino, R; Ciliberto, G | |
A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions | 1-gen-2022 | Donzelli, Sara; Cioce, Mario; Sacconi, Andrea; Zanconato, Francesca; Daralioti, Theodora; Goeman, Frauke; Orlandi, Giulia; Di Martino, Simona; Fazio, Vito Michele; Alessandrini, Gabriele; Telera, Stefano; Carosi, Mariantonia; Ciliberto, Gennaro; Botti, Claudio; Strano, Sabrina; Piccolo, Stefano; Blandino, Giovanni |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 491
- 1 Contributo su Rivista::1.1 Arti... 490
- 6 Brevetti 29
- 6 Brevetti::6.1 Brevetto 29
- 2 Contributo in Volume 24
- 2 Contributo in Volume::2.1 Contr... 24
- 4 Contributo in Atti di Convegno ... 8
- 4 Contributo in Atti di Convegno ... 4
- 4 Contributo in Atti di Convegno ... 3
- 5 Altro 3
- 5 Altro::5.12 Altro 3
- 1 Contributo su Rivista::1.5 Abst... 1
- 4 Contributo in Atti di Convegno ... 1
Data di pubblicazione
- 2020 - 2024 129
- 2010 - 2019 172
- 2000 - 2009 96
- 1990 - 1999 115
- 1980 - 1989 42
- 1978 - 1979 1
Editore
- Oxford University Press 2
- ELSEVIER SCIENCE PUBLISHER B.V. 1
- IntechOpen 1
- IRL press at Oxford University Press 1
- Marcel Dekker, Inc. 1
- Società Editrice Romana 1
- Società Editrice Universo 1
- Springer, Boston, MA 1
- Taylor & Francis 1
Rivista
- JOURNAL OF TRANSLATIONAL MEDICINE 35
- JOURNAL OF EXPERIMENTAL & CLINICA... 24
- EMBO JOURNAL 21
- CANCERS 14
- ONCOTARGET 14
- HUMAN GENE THERAPY 12
- NUCLEIC ACIDS RESEARCH 12
- PROCEEDINGS OF THE NATIONAL ACADE... 12
- JOURNAL OF CELLULAR PHYSIOLOGY 10
- CELL DEATH & DISEASE 8
Keyword
- Humans 19
- COVID-19 18
- SARS-CoV-2 14
- Female 10
- Viral 9
- Aged 7
- Antibodies 7
- Immunotherapy 7
- Melanoma 7
- Male 6
Lingua
- eng 468
- ita 8
- ger 1
Accesso al fulltext
- no fulltext 554
- reserved 1